Eclectic Associates Inc. ADV Has $1.21 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Eclectic Associates Inc. ADV boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,329 shares of the company’s stock after acquiring an additional 93 shares during the period. Eclectic Associates Inc. ADV’s holdings in Johnson & Johnson were worth $1,205,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC lifted its holdings in shares of Johnson & Johnson by 1.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 71,517 shares of the company’s stock valued at $10,343,000 after purchasing an additional 1,226 shares in the last quarter. CX Institutional lifted its stake in Johnson & Johnson by 18.6% in the fourth quarter. CX Institutional now owns 58,313 shares of the company’s stock valued at $8,433,000 after buying an additional 9,146 shares in the last quarter. Impact Partnership Wealth LLC boosted its holdings in shares of Johnson & Johnson by 10.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 7,925 shares of the company’s stock valued at $1,146,000 after buying an additional 765 shares during the period. Southland Equity Partners LLC raised its holdings in shares of Johnson & Johnson by 21.0% during the fourth quarter. Southland Equity Partners LLC now owns 22,440 shares of the company’s stock worth $3,245,000 after acquiring an additional 3,900 shares during the period. Finally, LexAurum Advisors LLC lifted its position in Johnson & Johnson by 1.7% in the 4th quarter. LexAurum Advisors LLC now owns 55,655 shares of the company’s stock valued at $8,049,000 after acquiring an additional 913 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Barclays decreased their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $152.91 on Tuesday. The business has a 50-day simple moving average of $147.85 and a two-hundred day simple moving average of $156.10. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market cap of $368.15 billion, a PE ratio of 22.99, a PEG ratio of 2.45 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same period last year, the company earned $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.